<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432028</url>
  </required_header>
  <id_info>
    <org_study_id>05053</org_study_id>
    <nct_id>NCT01432028</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Study of Different Hormone Therapies in Recent Menopause Women</brief_title>
  <official_title>Polymorphisms in Genes Encoding the Estrogen Metabolism Enzymes and Effects of Hormone Therapy for Oral Low Dose or Not Oral on Variables Related Endothelial Function, Inflammation and Metabolic Profile in Patients in Recent Menopause Study Pharmacogenetic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denusa Wiltgen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Rio Grande do Sul</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is cross-over, randomized clinical trial, with objective to evaluate the effects of
      low-dose oral hormone therapy and non-oral hormone therapy on endothelial function markers
      (fibrinogen, von Willebrand factor, c-reactive protein), natriuretic peptide and on
      anthropometric, metabolic and hormonal variables in early and healthy postmenopausal women
      and analyzing polymorphisms in the estrogen receptor gene and FTO polymorphisms

      Patients will be randomized to receive oral hormone treatment or non-oral hormone treatment

      The investigators hypothesis is that a different genotypes in the receptor estrogen gene and
      FTO may have an influences on treatment response in metabolic markers and cardiovascular risk
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polymorphisms of estrogen receptor</measure>
    <time_frame>six months</time_frame>
    <description>Influence of 4 polymorphisms (PVUII, ALUI, RSAI and BSTUI) on the effect of different treatment regimens. Change from Baseline in weight, waist circumference, BMI, systolic and diastolic blood pressure, fasting glucose, glucose at 120 min, Fasting insulin, HOMA, Cholesterol, HDL-c, LDL-c, Triglycerides, Von Willebrand Factor, Fibrinogen, Testosterone and C-reactive protein at six months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Polymorphisms in the fat mass-and obesity-associated (FTO) gene</measure>
    <time_frame>Six Months</time_frame>
    <description>Influence of 2 polymorphisms (rs9939609 and rs8050136) on the effect of different treatment regimens. Change from Baseline in weight, waist circumference, BMI, systolic and diastolic blood pressure, fasting glucose, glucose at 120 min, Fasting insulin,HOMA, Cholesterol, HDL-c, LDL-c, Triglycerides, Von Willebrand Factor, Fibrinogen, Testosterone and C-reactive protein at six months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effects of hormone therapy on C reactive protein, atrial natriuretic peptide and cardiovascular risk factors in postmenopause.</measure>
    <time_frame>Six months</time_frame>
    <description>To assess the effects of oral low-dose and non-oral hormone therapy (HT) on ultra-sensitive C reactive protein (CRP), atrial natriuretic peptide (ANP), and cardiovascular risk factors in postmenopause.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Postmenopause</condition>
  <arm_group>
    <arm_group_label>Non-oral hormone therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral homone therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>estradiol 1mg and drospirenone 2 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol and Progesterone</intervention_name>
    <description>3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month</description>
    <arm_group_label>Non-oral hormone therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol and Drospirenone</intervention_name>
    <description>oral estradiol 1mg and drospirenone 2 mg/day</description>
    <arm_group_label>oral homone therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  last menstrual period between 6 months and 3 years before the beginning of the study
             plus FSH levels higher than 35 IU/L;

          -  age between 42 and 58 years;

          -  no use of any medication known to interfere with hormonal, glucose, or lipoprotein
             levels in the past 3 months;

          -  no use of steroidal or no steroidal anti-inflammatory drugs in the last 15 days.

        Exclusion criteria:

          -  patients with diabetes,

          -  previous hysterectomy,

          -  endometrial thickness &gt;0.5cm,

          -  history of cancer,

          -  thromboembolism, or

          -  established cardiovascular disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>42 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poli Mara Spritzer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Rio Grande do Sul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2011</study_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Rio Grande do Sul</investigator_affiliation>
    <investigator_full_name>Denusa Wiltgen</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

